JAZZ PHARMACEUTICALS PLC (JAZZ) Fundamental Analysis & Valuation

NASDAQ:JAZZ • IE00B4Q5ZN47

187.01 USD
-1.68 (-0.89%)
Last: Mar 5, 2026, 11:12 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This JAZZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, JAZZ scores 4 out of 10 in our fundamental rating. JAZZ was compared to 193 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

6

1. JAZZ Profitability Analysis

1.1 Basic Checks

  • In the past year JAZZ was profitable.
  • In the past year JAZZ had a positive cash flow from operations.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • Of the past 5 years JAZZ 4 years had a positive operating cash flow.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • JAZZ has a Return On Assets of -3.24%. This is in the better half of the industry: JAZZ outperforms 75.13% of its industry peers.
  • The Return On Equity of JAZZ (-9.31%) is better than 76.17% of its industry peers.
  • JAZZ's Return On Invested Capital of 3.95% is amongst the best of the industry. JAZZ outperforms 82.90% of its industry peers.
  • JAZZ had an Average Return On Invested Capital over the past 3 years of 3.85%. This is significantly below the industry average of 12.91%.
  • The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • The Operating Margin of JAZZ (10.92%) is better than 83.94% of its industry peers.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • JAZZ's Gross Margin of 88.49% is amongst the best of the industry. JAZZ outperforms 91.19% of its industry peers.
  • In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. JAZZ Health Analysis

2.1 Basic Checks

  • JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for JAZZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • JAZZ has an Altman-Z score of 1.65. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
  • JAZZ's Altman-Z score of 1.65 is fine compared to the rest of the industry. JAZZ outperforms 61.66% of its industry peers.
  • JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
  • JAZZ's Debt to FCF ratio of 4.33 is amongst the best of the industry. JAZZ outperforms 84.97% of its industry peers.
  • A Debt/Equity ratio of 1.09 is on the high side and indicates that JAZZ has dependencies on debt financing.
  • The Debt to Equity ratio of JAZZ (1.09) is worse than 72.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.65
ROIC/WACC0.56
WACC7.1%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ has a worse Current ratio (1.65) than 66.84% of its industry peers.
  • A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ has a Quick ratio of 1.44. This is in the lower half of the industry: JAZZ underperforms 62.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. JAZZ Growth Analysis

3.1 Past

  • The earnings per share for JAZZ have decreased strongly by -61.30% in the last year.
  • Measured over the past years, JAZZ shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.04% on average per year.
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%

3.2 Future

  • Based on estimates for the next years, JAZZ will show a very strong growth in Earnings Per Share. The EPS will grow by 31.81% on average per year.
  • Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 7.16% on average per year.
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue Next Year4.81%
Revenue Next 2Y6.23%
Revenue Next 3Y7.11%
Revenue Next 5Y7.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

8

4. JAZZ Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 22.81 indicates a rather expensive valuation of JAZZ.
  • Based on the Price/Earnings ratio, JAZZ is valued cheaper than 80.31% of the companies in the same industry.
  • JAZZ's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.03.
  • With a Price/Forward Earnings ratio of 7.50, the valuation of JAZZ can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 92.75% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 25.11. JAZZ is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 22.81
Fwd PE 7.5
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaply inside the industry as 84.46% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 91.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.29
EV/EBITDA 12.47
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as JAZZ's earnings are expected to grow with 49.05% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y75.53%
EPS Next 3Y49.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAZZ Dividend Analysis

5.1 Amount

  • No dividends for JAZZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ Fundamentals: All Metrics, Ratios and Statistics

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (3/5/2026, 11:12:46 AM)

187.01

-1.68 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners104.02%
Inst Owner Change0.46%
Ins Owners2.48%
Ins Owner Change-0.22%
Market Cap11.51B
Revenue(TTM)N/A
Net Income(TTM)-368.48M
Analysts85.22
Price Target223.78 (19.66%)
Short Float %10.17%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.29%
PT rev (3m)15.46%
EPS NQ rev (1m)1.72%
EPS NQ rev (3m)1.53%
EPS NY rev (1m)1.18%
EPS NY rev (3m)54.77%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)1.02%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 22.81
Fwd PE 7.5
P/S 2.77
P/FCF 9.29
P/OCF 8.27
P/B 2.91
P/tB N/A
EV/EBITDA 12.47
EPS(TTM)8.2
EY4.38%
EPS(NY)24.93
Fwd EY13.33%
FCF(TTM)20.13
FCFY10.76%
OCF(TTM)22.61
OCFY12.09%
SpS67.54
BVpS64.31
TBVpS-39.54
PEG (NY)0.11
PEG (5Y)N/A
Graham Number108.93
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.65
F-Score5
WACC7.1%
ROIC/WACC0.56
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%
Revenue Next Year4.81%
Revenue Next 2Y6.23%
Revenue Next 3Y7.11%
Revenue Next 5Y7.16%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.5%
EBIT Next 3Y6.55%
EBIT Next 5Y7.24%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 8 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 204.02% in the next year.